InflaRx N.V. (IFRX) stock
IFRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.17−0.07 (-5.65%)
Close on Nov 13, 2026Market cap $84.58MP/E –Yield –
InflaRx EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was -0.68 EUR. The highest annual figure on record is -0.67 EUR in fiscal 2022.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -0.68 EUR | – |
| FY2024 | Dec 31, 2024 | -0.78 EUR | – |
| FY2023 | Dec 31, 2023 | -0.78 EUR | – |
| FY2022 | Dec 31, 2022 | -0.67 EUR | – |
| FY2021 | Dec 31, 2021 | -1.10 EUR | – |
| FY2020 | Dec 31, 2020 | -1.26 EUR | – |
| FY2019 | Dec 31, 2019 | -2.05 EUR | – |
| FY2018 | Dec 31, 2018 | -1.19 EUR | – |
| FY2017 | Dec 31, 2017 | -2.58 EUR | – |
| FY2016 | Dec 31, 2016 | -3.80 EUR | – |
| FY2015 | Dec 31, 2015 | -2.10 EUR | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2025 | Jun 30, 2025 | -0.21 EUR | – |
| Q2 FY2024 | Jun 30, 2024 | -0.24 EUR | – |
| Q2 FY2023 | Jun 30, 2023 | -0.14 EUR | – |
| Q2 FY2022 | Jun 30, 2022 | 0.01 EUR | – |
| Q2 FY2021 | Jun 30, 2021 | -0.33 EUR | – |
| Q2 FY2019 | Jun 30, 2019 | -0.59 EUR | – |
| Q2 FY2018 | Jun 30, 2018 | -0.10 EUR | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?